The MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer

dc.AffiliationOctober University for modern sciences and Arts MSA
dc.contributor.authorMohamed S. Othman,
dc.contributor.authorMohamed Tharwat Elabbasy,
dc.contributor.authorAhmed M. Aref,
dc.contributor.authorAya A. Altaleb
dc.contributor.authorMarwa Hamdy Mohammed,
dc.contributor.authorDoaa Atef Mohamed Soliman,
dc.contributor.authorNashwa El-Khazragy,
dc.date.accessioned2024-11-06T13:16:37Z
dc.date.available2024-11-06T13:16:37Z
dc.date.issued2023-10
dc.descriptionmiRNA, micro-RNA; HER2-MBC, HER2-positive Metastatic Breast cancer; BC, breast cancer; BL, baseline; 1C, after completing Trastuzumab treatment; FOXP3, forkhead box P3; HER2, human epidermal growth factor receptor 2; TTP, time to progression; STROBE, Strengthening the Reporting of Observational Studies in Epidemiology; PASS, Power Analysis and Sample Size Software; ROC, Receiving operating characteristics curve; CI, 95% confidence interval; AUC, area under the curve.
dc.description.abstractPurpose: Resistance to Trastuzumab is a significant challenge in the management of HER2-positive Metastatic Breast cancer (HER2-MBC), and a better understanding of the molecular causes of resistance is required to develop more effective treatment plans. While elevated plasma levels of miR-200 and FOXP3 have been linked to breast cancer progression and treatment response, no clinical studies have confirmed these results. Methods: The study involved 40 patients with HER2-positive metastatic breast cancer (HER2-MBC). The expression levels of miR-200c-3p and the FOXP3 gene were assessed in plasma samples at two time points: baseline (BL) and after the consent completion of one cycle of Trastuzumab, utilizing quantitative polymerase chain reaction (qPCR). Clinical response to Trastuzumab was evaluated 12 months post-therapy and correlated with the time to progression (TTP) through Kaplan-Meier analysis. Results: Low plasma expression level of miR-200c-3p was detected before therapy in HER2-MBC, compared to healthy controls, and decreased dramatically in the follow-up sample at disease progression, while increased after one cycle of Trastuzumab therapy in patients who were sensitive to Trastuzumab. At baseline, a low expression level of miR-200c was significantly associated with overexpression of FOXP3, poor prognosis, and shorter time to progression. Conclusions: The findings suggest that miR-200c-3p may be a promising biomarker for predicting the response to Trastuzumab in HER2-MBC patients.
dc.description.urihttps://www.scimagojr.com/journalsearch.php?q=13158&tip=sid&clean=0
dc.identifier.doiDOI: 10.1177/15330338241292226
dc.identifier.urihttps://repository.msa.edu.eg/handle/123456789/6189
dc.language.isoen
dc.publisherSage: Technology in Cancer Research & Treatment
dc.relation.ispartofseries2 Technology in Cancer Research & Treatment; Volume 23: 1-10
dc.subjectTrastuzumab
dc.subjectHER2-positive breast cancer
dc.subjectmetastatic breast cancer
dc.subjectdrug resistance
dc.subjectmiR-200c
dc.subjectFOXP3
dc.subjectpredictor biomarker
dc.titleThe MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Bio 1.pdf
Size:
699.21 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
51 B
Format:
Item-specific license agreed upon to submission
Description: